Iain S McGregor Selected Research

Therapeutics

1/2021	The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations.
10/2020	Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies.
11/2019	Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Iain S McGregor Research Topics

Disease

14	Epilepsy (Aura) 06/2022 - 01/2016
12	Hypothermia 01/2022 - 08/2003
11	Seizures (Absence Seizure) 01/2022 - 01/2013
7	Myoclonic Epilepsies (Myoclonic Encephalopathy) 01/2022 - 11/2019
7	Schizophrenia (Dementia Praecox) 01/2017 - 08/2010
7	Body Weight (Weight, Body) 05/2014 - 04/2004
7	Hyperthermia 08/2009 - 06/2002
6	Substance-Related Disorders (Drug Abuse) 05/2022 - 10/2010
5	Pica (Geophagia) 02/2019 - 01/2017
4	Chronic Pain 10/2021 - 01/2019
4	Anxiety Disorders (Anxiety Disorder) 09/2021 - 11/2005
4	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2018 - 03/2012
3	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2022 - 01/2020
3	Pain (Aches) 01/2022 - 12/2014
3	Pneumococcal Meningitis (Streptococcus pneumoniae Meningitis) 11/2019 - 08/2014
3	Infections 11/2019 - 02/2004
3	Marijuana Abuse (Cannabis Abuse) 01/2018 - 01/2013
3	Bradycardia 10/2017 - 09/2015
3	Alcoholism (Alcohol Abuse) 05/2017 - 09/2004
3	Mental Disorders (Mental Disorder) 10/2016 - 03/2013
2	Psychotic Disorders (Schizoaffective Disorder) 05/2022 - 01/2019
2	Sleep Wake Disorders 01/2022 - 10/2020
2	Sleep Apnea Syndromes (Sleep Apnea) 01/2022 - 10/2020
2	Cancer Pain 10/2021 - 01/2018
2	Catalepsy 01/2020 - 08/2010
2	Inflammation (Inflammations) 12/2019 - 09/2013
2	Cardiotoxicity 01/2019 - 01/2018
2	Anorexia Nervosa 01/2019 - 01/2018
2	Multiple Sclerosis 01/2019 - 03/2014
2	Memory Disorders (Memory Loss) 01/2017 - 04/2008
2	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 10/2014 - 01/2013
2	Meningitis 08/2014 - 08/2014
2	Drug Fever 01/2007 - 08/2003
2	Long Term Adverse Effects 08/2005 - 04/2004
1	Necrosis 03/2022
1	Drug-Related Side Effects and Adverse Reactions 01/2022
1	COVID-19 01/2021

Drug/Important Bio-Agent (IBA)

18	CannabinoidsIBA 01/2022 - 06/2004
15	Pharmaceutical PreparationsIBA 06/2022 - 08/2003
11	CannabidiolIBA 06/2022 - 08/2010
11	Anticonvulsants (Antiepileptic Drugs)IBA 01/2022 - 11/2007
11	Dronabinol (THC)FDA LinkGeneric 10/2021 - 04/2008
9	Oxytocin (Pitocin)FDA LinkGeneric 01/2018 - 10/2010
9	N-Methyl-3,4-methylenedioxyamphetamine (MDMA)IBA 08/2009 - 06/2002
8	Proteins (Proteins, Gene)FDA Link 01/2016 - 06/2006
6	Medical MarijuanaIBA 01/2022 - 01/2017
5	Serotonin (5 Hydroxytryptamine)IBA 09/2013 - 08/2003
4	Methamphetamine (Desoxyn)FDA LinkGeneric 05/2022 - 08/2005
4	Anti-Anxiety Agents (Anxiolytics)IBA 09/2021 - 11/2007
4	NeuropeptidesIBA 05/2017 - 10/2010
4	Neuregulin-1 (Neuregulin 1)IBA 01/2017 - 06/2011
3	EndocannabinoidsIBA 01/2022 - 06/2011
3	Clobazam (HR 376)IBA 12/2021 - 11/2019
3	EnzymesIBA 09/2021 - 02/2004
3	SolutionsIBA 01/2020 - 01/2013
3	RimonabantIBA 01/2020 - 06/2004
3	5F-CUMYL-PICAIBA 01/2019 - 01/2017
3	Antidepressive Agents (Antidepressants)IBA 10/2014 - 11/2007
2	cannabigerolic acidIBA 01/2022 - 12/2021
2	T-Type Calcium Channels (T-Type Calcium Channel)IBA 01/2022 - 01/2022
2	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2022 - 08/2010
2	Illicit Drugs (Recreational Drugs)IBA 01/2022 - 08/2009
2	Aminobutyrates (Aminobutyric Acid)IBA 01/2020 - 12/2019
2	cumyl-PINACAIBA 02/2019 - 10/2017
2	indoleIBA 01/2019 - 01/2017
2	methyl 2- (1- (4- fluorobenzyl)- 1H- indazole- 3- carboxamido)- 3- methylbutanoateIBA 01/2019 - 01/2018
2	Cannabinoid Receptor AgonistsIBA 01/2018 - 06/2011
2	nabiximols (Sativex)IBA 01/2018 - 03/2014
2	N- (1- amino- 3- methyl- 1- oxobutan- 2- yl)- 1- pentyl- 1H- indazole- 3- carboxamideIBA 01/2017 - 09/2015
2	AB-FUBINACAIBA 01/2017 - 09/2015
2	Tryptophan (L-Tryptophan)FDA Link 10/2016 - 08/2014
2	Ethanol (Ethyl Alcohol)IBA 03/2015 - 03/2012
2	Antipsychotic Agents (Antipsychotics)IBA 10/2014 - 01/2013
2	Methylphenidate (Ritalin)FDA LinkGeneric 10/2014 - 01/2013
2	CytokinesIBA 08/2014 - 02/2004
2	Sucrose (Saccharose)IBA 05/2014 - 01/2013
1	Terpenes (Terpenoids)IBA 06/2022
1	SodiumIBA 06/2022
1	InterleukinsIBA 03/2022
1	LipopolysaccharidesIBA 03/2022
1	MyoglobinIBA 03/2022
1	olivetolic acidIBA 01/2022
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022
1	EstersIBA 01/2022
1	SolventsIBA 01/2022
1	MercuryIBA 01/2022
1	ArsenicIBA 01/2022
1	Heavy MetalsIBA 01/2022
1	CannabinolIBA 01/2022
1	CadmiumIBA 01/2022
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2022
1	Escitalopram FDA Link 09/2021
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 09/2021
1	Citalopram FDA LinkGeneric 09/2021
1	Therapeutic UsesIBA 03/2021
1	OilsIBA 01/2021

Therapy/Procedure

6	Induced Hyperthermia (Thermotherapy) 01/2022 - 06/2004
3	Therapeutics 01/2021 - 11/2019
2	Drug Therapy (Chemotherapy) 01/2019 - 09/2004
2	Induced Hypothermia 10/2017 - 09/2015